首页> 美国卫生研究院文献>Cancer Medicine >Response‐adapted treatment with rituximab bendamustine mitoxantrone and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

【2h】

Response‐adapted treatment with rituximab bendamustine mitoxantrone and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

机译：一线免疫化疗后复发或难治性滤泡性淋巴瘤患者应用利妥昔单抗苯达莫司汀米托蒽醌和地塞米松进行适应性治疗然后进行利妥昔单抗维持：RBMDGELTAMO08 II期试验的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy.

机译：对于免疫化学疗法后复发或难治的滤泡性淋巴瘤患者，对于最佳挽救疗法尚缺乏共识。

著录项

期刊名称 Cancer Medicine
作者
Francisco‐Javier Peñalver; José‐Antonio Márquez; Soledad Durán; Pilar Giraldo; Alejandro Martín; Carlos Montalbán; Juan‐Manuel Sancho; María‐José Ramírez; María‐José Terol; Francisco‐Javier Capote; Antonio Gutiérrez; Blanca Sánchez; Andrés López; Antonio Salar; Gil Rodríguez‐Caravaca; Miguel Canales; María‐Dolores Caballero; on behalf of GELTAMO (The Spanish Lymphoma Cooperative Group);
展开▼
作者单位

展开▼
年(卷),期 2019(8),16
年度 2019
页码 -1
总页数 12
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
bendamustine; follicular lymphoma; immunochemotherapy; refractory; relapsed;

机译：苯达莫司汀;滤泡性淋巴瘤;免疫化疗;难治性;复发;

相似文献

外文文献
中文文献
专利

1. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). [J] . Weide R, Hess G, Koppler H, Leukemia and lymphoma . 2007,第7期

机译：苯达莫司汀/米托蒽醌/利妥昔单抗在利妥昔单抗预处理的复发性或难治性惰性淋巴瘤和套细胞淋巴瘤中具有很高的抗淋巴瘤活性。德国低级淋巴瘤研究小组（GLSG）的多中心II期研究。
2. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group [J] . Rueda Antonio, Calvo Virginia, Casanova Maria, Leukemia and lymphoma . 2019,第5a6期

机译：免疫化学治疗卵泡淋巴瘤患者中蓖麻油蛋白 - 苯德米司汀作为二线治疗的疗效：西班牙淋巴瘤肿瘤学群的II期试验
3. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) [J] . Boccomini Carola, Ladetto Marco, Rigacci Luigi, British Journal of Haematology . 2021,第2期

机译：简短的Rituximab，Bendamustine，Mitoxantrone（R-BM）诱导，然后是Rituximab巩固在老年晚期卵泡淋巴瘤患者中：Bondazione Italiana Linfomi的II期研究（FIL）
4. RISK-ADAPTED INTRAVENOUS MELPHALAN WITH ADJUVANT THALIDOMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED UNTREATED PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS: INTERIM REPORT OF A PHASE II TRIAL [C] . RL Comenzo, P Zhou, L Reich, International Symposium on Amyloidosis . 2005

机译：风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松，用于新诊断的未经治疗的全身淀粉样蛋白症患者：II期试验的中期报告
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma [O] . Wendy B.C. Stevens, Katerina Bakunina, Marloes Cuijpers, 2020

机译：HOVON110 / ReBeL研究：来那度胺利妥昔单抗联合或不联合苯达莫司汀治疗复发/难治性滤泡性淋巴瘤患者的随机I / II期I / II期研究结果
7. Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial [O] . Francisco‐Javier Peñalver, José‐Antonio Márquez, Soledad Durán, 2019

机译：用Rituximab，Bendamustine，Mitoxantrone和地塞米松的响应适应治疗随后在一线免疫化疗法后复发或耐火滤饼淋巴瘤患者中的Rituximab维持：RBMDGETTAMO08期二期试验的结果

Response‐adapted treatment with rituximab bendamustine mitoxantrone and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

摘要

著录项

相似文献

相关主题

期刊订阅